Catalysis of entanglement and other quantum resources.

In chemistry, a catalyst is a substance which enables a chemical reaction or increases its rate, while remaining unchanged in the process. Instead of chemical reactions,quantum catalysisenhances our ability to convert quantum states into each other under physical constraints. The nature of the constraints depends on the problem under study and can arise, e.g. from energy preservation. This article reviews the most recent developments in quantum catalysis and gives a historical overview of this research direction. We focus on the catalysis of quantum entanglement and coherence, and also discuss this phenomenon in quantum thermodynamics and general quantum resource theories. We review applications of quantum catalysis and also discuss the recent efforts on universal catalysis, where the quantum state of the catalyst does not depend on the states to be transformed. Catalytic embezzling is also considered, a phenomenon that occurs if the catalyst's state can change in the transition.

Cryotherapy and its applications in the management of urologic malignancies: a review of its use in prostate and renal cancers.

Cryotherapy has been established as an ablative modality for the treatment of a wide range of malignancies. Being minimally invasive, it is associated with less morbidity than conventional extirpative surgical procedures. In recent years, it has been used with success for treating two of the common urologic malignancies, that is, prostate and renal cancer. In this review, we highlight the role of cryotherapy as a treatment modality, the proposed destructive mechanisms of action and the risks of its use in the management of prostate and renal malignancy.

The role of enzalutamide in the treatment of castration-resistant prostate cancer.

Prostate cancer is the most common solid organ cancer affecting the male population. Men with metastatic prostate cancer treated with androgen ablation therapy often respond rapidly, with improvement in bone pain and decreases in serum prostate-specific antigen. However, almost all patients progress to the castration-resistant state and abiraterone acetate was the last treatment available with proven survival benefit. Enzalutamide (formerly MDV3100) is an androgen receptor signaling inhibitor that has been shown to improve survival in men with metastatic castration-resistant prostate cancer previously treated with chemotherapy. In this article we discuss the characteristics of enzalutamide and provide a review of its clinical development.

The role of abiraterone in the management of metastatic castration-resistant prostate cancer.

Prostate cancer is the most common solid-organ cancer affecting the male population. Men with metastatic prostate cancer treated with androgen ablation therapy often respond rapidly, with improvement in bone pain and decreases in serum prostate-specific antigen. However, almost all patients progress to the castrate-resistant state and until recently chemotherapy was the only treatment available with proven survival benefit. Abiraterone is a new class of anti-androgen with proven survival benefit post-chemotherapy. In this review we discuss the characteristics of abiraterone and the clinical trials that led to its approval for the treatment of patients with prostate cancer.

A management algorithm for hematospermia.

The presence of blood in the semen--hematospermia--is an anxiety-provoking but usually self-limiting condition. Its exact incidence remains unclear. The risk of underlying malignancy, despite being very low, drives evaluation. There is confusion amongst clinicians as to how best to refer, evaluate and treat men with hematospermia. We have reviewed the literature in an attempt to present a cohesive view of the etiologies and diagnostic and management strategies in patients with this condition.